The Antibiotic Paradox

The Antibiotic Paradox

The antibiotic paradox: why companies can’t afford to create life-saving drugs

Antibiotic resistance in patients is a dangerous slurry composed of antibiotic overuse, diagnostic limitations, and a relatively small list of diversified antibiotics. But why don’t drug manufacturers simply develop new antibiotics? This was, after all, the most common pharmaceutical product in the early days of modern medicine. A publication from Nature details the challenges in a case study on Paratek Pharmaceuticals.

In a nutshell, economics are the main factor at play. “A new antibiotic needs to make at least $300 million in annual revenue to be sustainable.” But other challenges also exist, like an abysmally low 14% approval rating for trials of new antibiotics, biomechanical difficulties, short antibiotic lifespans, and an intentionally slow deployment of new antibiotics to curb future resistance. However, while it is difficult, new antibiotics are in the works. This, combined with clinician antibiotic stewardship, paves a potential path forward.

 

https://www.nature.com/articles/d41586-020-02418-x?utm_campaign=Educational%20Content&utm_content=205796280&utm_medium=social&utm_source=linkedin&hss_channel=lcp-69477560